Compare Tango Therapeutics Inc. (TNGX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B), while YieldMax Universe Fund of Option Income ETFs trades at $7.34 (market cap $365.95M). The key difference: Tango Therapeutics Inc. is far larger — about 10.2× YieldMax Universe Fund of Option Income ETFs's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and YieldMax Universe Fund of Option Income ETFs for 57 Days on average.
| TNGX | YMAX | |
|---|---|---|
Market Cap | $3.75B | $365.95M |
Volume | 9,619,106 | 1,000,945 |
Sector | Health | Income / Options Overlay |
52-Week High | $32.90 | $12.60 |
52-Week Low | $7.50 | $7.27 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $2.77B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
YMAX trades at $7.61 with minimal daily movement (+0.13%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The fund maintains a high distribution policy with weekly dividends, but faces concerns about NAV erosion and sustainability. Recent portfolio adjustments aim to address performance issues while maintaining the ~40%+ annualized yield.
The outlook remains cautious due to structural concerns about distribution sustainability and NAV erosion. While the high yield attracts income investors, the fund's reverse split potential and stacked fee structure present significant risks. Analyst sentiment is mixed, with some questioning the long-term viability of the current distribution model amid persistent principal decline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
